Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

BACKGROUND: We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre. METHODS: All adult patients with IBD on standard dosing CT-P13 (5 mg/kg 8 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbery, Isabel, Burdge, Gemma, Clark, Tanya, Broglio, Giacomo, Greer, Dan, Alakkari, Alaa, Selinger, Christian Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950917/
https://www.ncbi.nlm.nih.gov/pubmed/36813298
http://dx.doi.org/10.1136/bmjgast-2023-001105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950917/
https://www.ncbi.nlm.nih.gov/pubmed/36813298
http://dx.doi.org/10.1136/bmjgast-2023-001105

Ejemplares similares